Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds

Journal of the American College of Cardiology

Volumn 47, Issue 6, 2006, Pages 1093-1100

  Grundy, Scott M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ATHEROGENIC DIET; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC NEUROPATHY; DISEASE COURSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEALTH PRACTITIONER; HEART ARRHYTHMIA; HEART FAILURE; HEREDITY; HUMAN; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; RISK FACTORS; TERMINOLOGY;

EID: 33644898538     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.11.046     Document Type: Review

References (92)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
3. American Diabetes Association The National Heart, Lung, and Blood Institute The Juvenile Diabetes Foundation International The National Institute of Diabetes and Digestive and Kidney Diseases The American Heart Association Diabetes mellitus a major risk factor for cardiovascular disease Circulation 100 1999 1132 1133
4. S.M. Grundy, J.I. Cleeman, S.R. Daniels Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary Circulation 112 2005 e285 e290
5. S.M. Grundy, J.I. Cleeman, S.R. Daniels Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752
6. K.G.M.M. Alberti, P. Zimmet, J. Shaw IDF Epidemiology Task Force Consensus Group The metabolic syndrome - a new worldwide definition Lancet 366 2005 1059 1062
7. Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, S.B. Heymsfield The metabolic syndrome prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994 Arch Intern Med 163 2003 427 436
8. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report Obes Res 6 Suppl 2 1998 51S 209S
9. P.W. Wilson, R.B. A'Agostino, L. Sullivan, H. Parise, W.B. Kannel Overweight and obesity as determinants of cardiovascular risk the Framingham experience Arch Intern Med 162 2002 1867 1872
10. C.A. Maggio, F.X. Pi-Sunyer Obesity and type 2 diabetes Metab Clin North Am 32 2003 805 822
11. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
12. F.X. Pi-Sunyer Medical hazards of obesity Ann Intern Med 119 1993 655 660
13. F.X. Pi-Sunyer The obesity epidemic pathophysiology and consequences of obesity Obesity Res 10 Suppl 2 2002 97S 104S
14. G.M. Reaven Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
15. G.M. Reaven Role of insulin resistance in human disease (syndrome X) an expanded definition Annu Rev Med 44 1993 121 131
16. E. Ferrannini, S.M. Haffner, B.D. Mitchell, M.P. Stern Hyperinsulinemia the key feature of a cardiovascular and metabolic syndrome Diabetologia 34 1991 416 422
17. R.A. DeFronzo, E. Ferrannini Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic cardiovascular disease Diabetes Care 14 1991 173 194
18. B. Balkau, M.A. Charles European Group for the Study of Insulin Resistance (EGIR) Comment on the provisional report from the WHO consultation Diabet Med 16 1999 442 443
19. D. Einhorn ACE position statement on insulin resistance syndrome Endocr Pract 9 2003 237 252
20. K.G. Alberti, P.Z. Zimmet Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 15 1998 539 553
21. D. Porte Jr Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction Ann N Y Acad Sci 892 1999 73 83
22. L. Groop Genetics of the metabolic syndrome Br J Nutr 83 Suppl 1 2000 S39 S48
23. B. Isomaa, P. Almgren, T. Tuomi Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683 689
24. H.M. Lakka, D.E. Laaksonen, T.A. Lakka The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
25. N. Sattar, A. Gaw, O. Scherbakova Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 108 2003 414 419
26. C.J. Girman, T. Rhodes, M. Mercuri 4S Group and the AFCAPS/TexCAPS Research Group The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Am J Cardiol 93 2004 136 141
27. S. Malik, N.D. Wong, S.S. Franklin Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults Circulation 110 2004 1245 1250
28. J.K. Olijhoek, Y. van der Graaf, J.D. Banga, A. Algra, T.J. Rabelink, F.L. Visseren SMART Study Group The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm Eur Heart J 25 2004 342 348
29. C.M. Alexander, P.B. Landsman, S.M. Teutsch, S.M. Haffner Third National Health and Nutrition Examination Survey (NHANES III) National Cholesterol Education Program (NCEP) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older Diabetes 52 2003 1210 1214
30. J.K. Ninomiya, G. L'Italien, M.H. Criqui, J.L. Whyte, A. Gamst, R.S. Chen Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey Circulation 109 2004 42 46
31. A.M. McNeill, W.D. Rosamond, C.J. Girman The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study Diabetes Care 28 2005 385 390
32. B.C. Solymoss, M.G. Bourassa, J. Lesperance Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease Coron Artery Dis 14 2003 207 212
33. H. Turhan, A.S. Yasar, N. Basar, A. Bicer, A.R. Erbay, E. Yetkin High prevalence of metabolic syndrome among young women with premature coronary artery disease Coron Artery Dis 16 2005 37 40
34. J.M. Dekker, C. Girman, T. Rhodes Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study Circulation 112 2005 666 673
35. D.E. Laaksonen, H.M. Lakka, L.K. Niskanen, G.A. Kaplan, J.T. Salonen, T.A. Lakka Metabolic syndrome and development of diabetes mellitus application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study Am J Epidemiol 156 2002 1070 1077
36. H.E. Resnick, K. Jones, G. Ruotolo Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians the strong heart study Diabetes Care 26 2003 861 867
37. B.E. Klein, R. Klein, K.E. Lee Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam Diabetes Care 25 2002 1790 1794
38. C. Lorenzo, M. Okoloise, K. Williams, M.P. Stern, S.M. Haffner The metabolic syndrome as predictor of type 2 diabetes the San Antonio heart study Diabetes Care 26 2003 3153 3159
39. M.I. Schmidt, B.B. Duncan, H. Bang The Atherosclerosis Risk in Communities Investigators Identifying individuals at high risk for diabetes The Atherosclerosis Risk in Communities study Diabetes Care 28 2005 2013 2018
40. P. Koskinen, M. Manttari, V. Manninen, J.K. Huttunen, O.P. Heinonen, M.H. Frick Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study Diabetes Care 15 1992 820 825
41. J.A.E. Manson, G.A. Colditz, M.J. Stampfer A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women Arch Intern Med 151 1991 1141 1147
42. J.B. Meigs, D.M. Nathan, P.W. Wilson, L.A. Cupples, D.E. Singer Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study Ann Intern Med 128 1998 524 533
43. K.G.M.M. Alberti, P. Zimmet, J. Shaw IDF Epidemiology Task Force Consensus Group The metabolic syndrome - a new worldwide definition Lancet 366 2005 1059 1062
44. R. Kahn, J. Buse, E. Ferrannini, M. Stern The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 28 2005 2289 2304
45. W.B. Kannel Importance of hypertension as a major risk factor in cardiovascular disease J. Genest E. Koiw O. Kuchel Hypertension Physiopathology and Treatment 1977 McGraw-Hill Book Company New York, NY 888 910
46. J. Stamler, R. Stamler, J.D. Neaton Blood pressure, systolic and diastolic, and cardiovascular risks. U.S. population data Arch Intern Med 153 1993 598 615
47. W.B. Kannel, M. Larson Long-term epidemiologic prediction of coronary disease. The Framingham experience Cardiology 82 1993 137 152
48. L. Ferrucci, C.D. Furberg, B.W. Penninx Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile Circulation 104 2001 1923 1926
49. A. Hamsten, U. de Faire, G. Walldius Plasminogen activator inhibitor in plasma risk factor for recurrent myocardial infarction Lancet 2 1987 3 9
50. T.W. Meade, V. Ruddock, Y. Stirling, R. Chakrabarti, G.J. Miller Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study Lancet 342 1993 1076 1079
51. H.P. Kohler, P.J. Grant Plasminogen-activator inhibitor type 1 and coronary artery disease N Engl J Med 342 2000 1792 1801
52. P.M. Ridker, N. Cook Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores Circulation 109 2004 1955 1959
53. J. Danesh, J.G. Wheeler, G.M. Hirschfield C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 2004 1387 1397
54. G. Assmann, H. Schulte, H. Funke, A. von Eckardstein The emergence of triglycerides as a significant independent risk factor in coronary artery disease Eur Heart J 19 Suppl M 1998 M8 M14
55. M.A. Austin, J.E. Hokanson, K.L. Edwards Hypertriglyceridemia as a cardiovascular risk factor Am J Cardiol 81 1998 7B 12B
56. B. Neal, S. MacMahon, N. Chapman Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs results of prospectively designed overviews of randomised trials Lancet 356 2000 1955 1964
57. G.L. Vega, S.M. Grundy Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease Curr Opin Lipidol 7 1996 209 216
58. G. Assmann, J.R. Nofer, H. Schulte Cardiovascular risk assessment in metabolic syndrome view from PROCAM Endocrinol Metab Clin North Am 33 2004 377 392
59. G.M. Reaven The insulin resistance syndrome definition and dietary approaches to treatment Annu Rev Nutr 25 2005 391 406
60. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 26 2003 3160 3167
61. F.J. Novoa, M. Boronat, P. Saavedra Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation the Telde study Diabetes Care 28 2005 2388 2393
62. P. Ilanne-Parikka, J.G. Eriksson, J. Lindstrom Finnish Diabetes Prevention Study Group Prevalence of the metabolic syndrome and its components findings from a Finnish general population sample and the Diabetes Prevention Study cohort Diabetes Care 27 2004 2135 2140
63. S.M. Haffner Cardiovascular risk factors and the prediabetic syndrome Ann Med 28 1996 363 370
64. T. Temelkova-Kurktschiev, E. Henkel, F. Schaper, C. Koehler, G. Siegert, M. Hanefeld Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil? Exp Clin Endocrinol Diabetes 108 2000 93 99
65. K.J. Hunt, R.G. Resendez, K. Williams, S.M. Haffner, M.P. Stern National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study Circulation 110 2004 1251 1257
66. S.M. Haffner, M.P. Stern, H.P. Hazuda, B.D. Mitchell, J.K. Patterson Cardiovascular risk factors in confirmed prediabetic individuals does the clock for coronary heart disease start ticking before the onset of clinical diabetes JAMA 263 1990 2893 2898
67. K.G. Alberti Problems related to definitions and epidemiology of type 2 (non-insulin-dependent) diabetes mellitus studies throughout the world Diabetologia 36 1993 978 984
68. C. Weyer, C. Bogardus, D.M. Mott, R.E. Pratley The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 104 1999 787 794
69. J.A. Colwell American Diabetes Association Aspirin therapy in diabetes Diabetes Care 27 Suppl 1 2004 S72 S73
70. R.B. Goldberg, M.J. Mellies, F.M. Sacks Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial Circulation 98 1998 2513 2519
71. S.M. Haffner, C.M. Alexander, T.J. Cook Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels subgroup analyses in the Scandinavian Simvastatin Survival Study Arch Intern Med 159 1999 2661 2667
72. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes a randomised placebo-controlled trial Lancet 361 2003 2005 2016
73. H.M. Colhoun, D.J. Betteridge, P.N. Durrington CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
74. N.M. Kaplan Management of hypertension in patients with type 2 diabetes mellitus guidelines based on current evidence Ann Intern Med 135 2001 1079 1083
75. A.V. Chobanian, G.L. Bakris, H.R. Black National Heart Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, National High Blood Pressure Education Program Coordinating Committee The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure the JNC 7 report JAMA 289 2003 2560 2572
76. S.M. Grundy Coronary plaque as a replacement for age as a risk factor in global risk assessment Am J Cardiol 88 2001 8E 11E
77. S.M. Grundy Atherosclerosis imaging for risk assessment and primary prevention of cardiovascular disease Prog Cardio Dis 46 2003 115 121
78. W.C. Knowler, E. Barrett-Connor, S.E. Fowler Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
79. J. Tuomilehto, J. Lindstrom, J.G. Eriksson Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
80. American Diabetes Association Clinical practice recommendations 2005 Diabetes Care 28 Suppl 1 2005 S1 S79
81. S.C. Smith Jr, S.N. Blair, R.O. Bonow AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Circulation 104 2001 1577 1579
82. T.A. Pearson, S.N. Blair, S.R. Daniels American Heart Association Science Advisory and Coordinating Committee AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases Circulation 106 2002 388 391
83. D.E. Arterburn, P.K. Crane, D.L. Veenstra The efficacy and safety of sibutramine for weight loss a systematic review Arch Intern Med 164; 2004 994 1003
84. M.P. Curran, L.J. Scott Orlistat a review of its use in the management of patients with obesity Drugs 64 2004 2845 2864
85. V. Di Marzo, I. Matias Endocannabinoid control of food intake and energy balance Nat Neurosci 8 2005 585 589
86. S.C. Black Cannabinoid receptor antagonists and obesity Curr Opin Investig Drugs 5 2004 389 394
87. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen Effects of cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
88. D. Osei-Hyiaman, M. DePetrillo, P. Pacher Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity J Clin Invest 115 2005 1298 1305
89. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells Mol Pharmacol 63 2003 908 914
90. J.A. Dormandy, B. Charbonnel, D.J. Eckland PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) a randomised controlled trial Lancet 366 2005 1279 1289
91. D. Barlocco Muraglitazar (Bristol-Myers Squibb/Merck) Curr Opin Investig Drugs 6 2005 427 434
92. B. Fagerberg, S. Edwards, T. Halmos Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population Diabetologia 48 2005 1716 1725